Mowoot, a CataloniaBio & HealthTech  member, has become the first Catalan medtech company to close a single  collaboration agreement with the largest funding platforms in Europe to launch its new round: Aescuvest (Germany), with the support of EITHealth, and Capital Cell, also CataloniaBio & HealthTech members. The new joint campaign totals 2 million euros.

Thanks to this unique collaboration, European investors of any size can invest in Mowoot through equity-funding with the assurance that the project has been reviewed and validated independently by both platforms. The new capital inflow will allow the company to boost its expansion plan focused on ...

The International Brain Research Organization-African Regional Committee (IBRO-ARC) is organizing a School on Genome Editing for Neuroscience Research in collaboration with a non-governmental organization (TReND in Africa). ZeClinics, a CataloniaBio & HealthTech  member, is joining the school with their scientific director, Vincenzo Di Donato, as an expert in the field of genomic modifications, and to represent ZeClinics as a worldwide reference company in zebrafish genetics.

The aim of the school is to promote research on genome editing in several non-rodent model systems in Africa, where, during the last few years, there is a growing interest from the local scientific community ...

Belgian biotechnology company Agomab Therapeutics NV (Agomab) has acquired Origo Biopharma, which is developing an innovative platform for TGF-beta-inhibiting locally acting drugs for the treatment of fibrosis in various tissues and cancer.

This biotechnology company based in Touro (Galicia) and Barcelona is funded by Asabys Partners, members of CataloniaBio &  HealthTech, and the Xunta de Galicia. Asabys Partners led a Seed round in June 2020, and since then have worked with the founders and management team to capture talent, expand the project portfolio, and develop the most advanced product to clinical stages.

The operation  with the Belgian biotechnology company is ...

CTIS will be the single-entry point for submitting clinical trial information in the EU. Asphalion, the international scientific and regulatory affairs consultancy company, and a CataloniaBio & HealthTech member, has been part of the EMA CTIS  stakeholder meetings and is also CTIS Master Trainer, thus has been closely involved in the implementation of the clinical trials regulation.

CTIs (Clinical Trial Information System) will go live when the Clinical Trial Regulation (CTR) becomes applicable on January 31st, 2022, and it will repeal the existing Clinical Trial Directive and national legislation that was put in place to implement the Directive. Companies ...

Drug discovery biotech firm Chemotargets, a CataloniaBio & HealthTech member, and the Centre for Genomic Regulation (CRG) have signed a strategic agreement to accelerate the development of new targeted therapies that respond to unmet clinical needs in different fields including cancer.

Chemotargets develops computational platforms for the design, optimization and safety evaluation of drugs. The biotech firm’s cutting-edge computational technologies can rapidly design potential new drug candidates for therapeutic targets that are difficult to treat and for which no identified drugs currently exist. The new partnership will leverage the CRG’s fundamental knowledge on the complexity of life, as well as ...

A new biotechnology-based company is born in the Institute for Bioengineering  of Catalonia (IBEC), member  of CataloniaBio & HealthTech. The IBEC Spin-off with private participation, Vitala Technologies, will offer innovative solutions for the analysis of drugs during their development, as well as the possibility to know in advance and in a personalized way, what will be the response of a patient to a certain treatment, aiming to accelerate and optimize the identification of  drugs to bring to the market.

Vitala combines innovative bioengineering technologies such as organs-on-a-chip and advanced imaging techniques, to offer unprecedented value in preclinical therapeutic compound research ...

The biotech company Archivel Farma has officially begun the clinical trial of its therapeutic vaccine RUTI® in India. The double-blind, randomized, placebo-controlled phase IIb clinical trial will investigate the efficacy of RUTI® as adjuvant of Tuberculosis (TB) chemotherapy and will recruit 90 patients with TB and 50 patients with multi-drug resistant TB (MDR-TB).

The clinical trials will be conducted by the CRO Clinical  Research Network India in two centers in the country, in New Delhi and Agartala. The first patient in the trial has been recruited on 30 September. "For Archivel it represents a great milestone since it brings the ...

ONA  Therapeutics announced the appointment of Dr Haijun Sun as Chief  Scientific Officer (CSO) and several appointments to its Scientific Advisory  Board (SAB). The biotech company, member of CataloniaBio &  HealthTech, is focused on the discovery and development of therapeutic biologics targeting lipid metabolism to treat advanced cancer.

Dr Haijun Sun brings over 20 years of industry experience spanning broad aspects of drug discovery & development, particularly targeting therapies against tumors and the tumor microenvironment. He joins ONA from GSK where, as Head of Antibody Pharmacology, he led a team of assay biologists and immunologists advancing over twenty antibody discovery ...

The U.S. Food and Drug Administration (FDA) approved Seglentis® (celecoxib and tramadol hydrochloride), a proprietary product developed by ESTEVE’s R&D team. This is ESTEVE's, CataloniaBio &  HealthTech member, first proprietary research product to enter the  United States market.

Seglentis® is the trade name for tablets that contain a co-crystal composed of celecoxib and tramadol hydrochloride. It is a new analgesic designed for acute pain  management in a multimodal treatment approach targeting four complementary pain  relief mechanisms. It offers a new treatment option for acute pain management aligned with the multimodal analgesia now considered standard of care.

The New ...

Grifols, a CataloniaBio & HealthTech member, welcomes the promising post-hoc analysis recently published by Biotest AG on the efficacy of trimodulin1 (IgM concentrate) in a relevant subgroup of severely ill COVID-19 patients.

In September, Grifols announced it entered into an agreement to acquire Tiancheng (Germany) Pharmaceutical  Holdings for EUR 1,100 million, the largest owner of Biotest AG. An alliance that will boost the availability of plasma-derived medicines and increase access for patients.

Less than one month after announcing the investment, Grifols welcomes Biotest’s recent and promising results: the analysis of the complete data set of ESsCOVID  (Escape from ...

MJN-neuro has opened crowdequity round of one million euros on the Capital  Cell platform to fund the business plan of the new device MJN-Seras, the first portable device that is able to predict the likelihood of suffering an epileptic seizure. The company, a CataloniaBio & HealthTech  member, has already exceeded one million euros in less than 5 months and expects to reach 120%. In addition, the round has been extended to allow the entry of a major Danish Family Office.

During this period, the value of the company has tripled, and, after the participation of American and Spanish investors, it ...

The investment company specializing in biotechnology and health, and a member of CataloniaBio & HealthTech, Capital  Cell, has raised 14 million euros. They are higher figures than the 13.5 million it raised throughout the 2020 financial year.

The director of the company, Daniel Oliver, sets the goal of reaching 16 million by the end of the current year. With this growth, Capital Cell could once again be the leader in crowdfunding in Spain in 2021.

Capital Cell was founded in 2015 as the first online investment platform in Europe specializing in biotechnology and health. Among the successes of the ...

A recent alliance between two CataloniaBio  & HealthTech members, the LEITAT  Technological Center and the Institute  for Bioengineering of Catalonia (IBEC), will give a new impulse in the development and application of cutting-edge technologies that will combine engineering and biology to find solutions to health problems. Both institutions have established a new agreement to promote innovation in different scientific and technological areas, including 3D bioprinting with bioinks.

The concept is based on an open creative space, in which researchers from both  institutions can collaborate with other institutions or companies from  different sectors, for the improvement and maturation of different technologies ...

The European Investment Bank (EIB) will provide Anaconda  Biomed, the medical device start-up and CataloniaBio & HelathTech  member, with venture debt funding of up to €10 million to support the  development of its second generation of catheter for the treatment of acute  ischemic stroke (AIS). This is the second venture debt operation in Spain backed by European Guarantee Fund (EGF) — part of the €540 billion EU response to the economic impact of COVID-19.

The EIB will provide long-term funding at favourable rates with flexible repayment. This will enable Anaconda Biomed to test the next generation of catheters to improve ...

Photo gallery

3D printing in the field of health is a well-established and well-known tool on a global scale. It called for the adaptation of the medical community, rethinking medical protocols, and has improved the efficiency and effectiveness of treatments. On the other hand, bioprinting still raises questions, but sounds like the new tool that could potentially revolutionize the industry.

CataloniaBio & HealthTech has debated the two tools in the 25th edition of the Lessons Learned forum, on October 7 at the Barcelona Science Park (PCB) and online (hybrid format) with entrepreneurs, hospitals and researchers from Catalonia working with them ...

BHV Partners, the venture builder specializing in the health sector and a member  of CataloniaBio & HealthTech, opens a new round of investment aimed at private investors in the health and financial sectors, to consolidate their growth. With this round of investment, it wants to raise 500,000 euros to  strengthen the professional team and develop its range of health projects.

Founded two years ago, BHV Partners has projects in its portfolio that are already advancing towards the market to offer solutions to unmet medical needs. These include Adan Medical, members of CataloniaBio &  HealthTech, who develop devices for anaphylaxis ...

Idneo  Medtech, member of  CataloniaBio & HealthTech, won the gold award in the 5th European Product Design Award in the Life Science Design, Medical, Scientific Machinery category for their design of the Universal Test Rider (UTR). The Universal  Test Reader (UTR) is Idneo Medtech's Point of Care solution that extends the functionality of conventional rapid test reader devices by developing the innovative vision of an AI-powered open test device able to interpret rapid tests from multiple vendors and formats. The UTR addresses analytical, epidemiological, and market needs, combining the quick, simple, inexpensive characteristics of rapid tests with the analytical robustness ...

Oxolife, a company associated with CataloniaBio  & HealthTech, has launched an international clinical trial to prove the effectiveness of its new treatment to improve the female fertility rate. It is the largest phase II study on female fertility conducted in Spain and it is aimed to improve the implantation of the embryo and increase the success rate of pregnancy, an unmet medical need as there is no therapy to improve embryonic implantation.

The trial has begun thanks to the round of  investment of 5 million euros that Oxolife captured in June 2020, which led Inveready together with the Center for ...

Mediktor, the healthtech company which provides a sophisticated pre-diagnosis medical assistant and a CataloniaBio & HealthTech  member, announced that it has raised a €11 million financing round to  keep on improving their elaborate technology and expand their international  presence.

The round was led by European healthtech growth capital investor MTIP. Existing investor Alta Life Sciences, also a CataloniaBio &  HealthTech member, participated as well.

Its technology identifies patient’s symptoms using natural language recognition, allowing the interpretation of more than one symptom at the same time. In the conversation with the medical assistant the questions require only simple responses and are ...

Inbiomotion, a CataloniaBio &HealthTech member, is developing a unique single-gene-based biomarker for the personalized adjuvant treatment of early-stage (stage I-III) breast cancer patients.  They recently announced the publication of the resultsof the prospectively-planned, retrospective analysis of clinical outcome data from a new clinical study in Journal of the National Cancer Institute, Cancer Spectrum.  The data show that in patients with MAF-negative tumors (determined with Inbiomotion’s proprietary MAF Test®), adjuvant treatment with clodronate was associated with a significant benefit in overall survival compared to placebo-treated control patients receiving the same standard of care.

Results confirm the company’s previous data (AZURE trial analyses ...